2017 December | The Journal of Targeted Therapies in Cancer

Immune Checkpoint Inhibition in Esophagogastric Cancers

December 29, 2017

Clinical Articles

The poor prognosis for patients with esophagogastric cancers (EGC) requires the development of newer more effective therapies to further improve the treatment outcomes for this disease. Immunotherapy is a novel treatment strategy that is dramatically changing the treatment landscape for several types of cancers. Cytotoxic T lymphocyte antigen-4 (CTLA-4) antibody and antagonists of the programmed death (PD)-1/PD-ligand 1 are essential immune checkpoint inhibitors that suppress T-cell activation.

Optimizing FLT3 Inhibitor Monotherapy in Acute Myeloid Leukemia

December 27, 2017

Clinical Articles

Acute myeloid leukemia (AML) therapy is guided mainly by cytogenetic profile, such as chromosomal duplication or deletion, and molecular mutations. FLT3 mutations are the most common genetic abnormalities detected in patients with AML and are usually associated with a high relapse rate and short overall survival. Given the dismal outcomes in patients with FLT3-mutant AML, a great effort has been underway over the last several years to develop clinically effective FLT3 inhibitors.

Novel Combination Shows Promising Responses in Pancreatic Cancer

December 19, 2017

Clinical Articles

The combination of the novel tumor-associated macrophage (TAM)-targeting agent cabiralizumab and the PD-1 inhibitor nivolumab (Opdivo) resulted in intriguing objective response rates in heavily pretreated patients with metastatic pancreatic cancer, according to findings from a phase I study presented at the 2017 SITC Annual Meeting.

Immunotherapy Overtakes Targeted Therapy as First-Line Standard of Care for mRCC

December 19, 2017

Clinical Articles

An extension in overall survival (OS) with the combination of nivolumab (Opdivo) and ipilimumab (Yervoy) has completely changed the standard of care for patients with metastatic renal cell carcinoma (mRCC), Thomas Powles, MD, MBBS, MRCP, told audience members during the 9th European Multidisciplinary Meeting on Urological Cancers.